An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Spectrum Pharmaceuticals (NASDAQ: SPPI) has appointed Brittany Bradrick to its Board of Directors, bringing 25 years of finance and corporate development experience. Her track record in M&A and the life sciences sector is expected to enhance the board's impact as the company moves forward.
Bradrick's leadership comes at a pivotal time with two product candidates under FDA review, indicating potential commercialization. Chairman William Ashton expressed confidence in her ability to contribute to Spectrum's mission of delivering innovative cancer treatments.
Positive
Brittany Bradrick's appointment is expected to strengthen the Board with her extensive experience in finance and strategy.
Her background in M&A and life sciences may drive the company's strategic initiatives effectively.
The timing of her appointment aligns with two product candidates under FDA review, potentially leading to future commercialization.
Negative
None.
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience.
“It’s my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum’s evolution,” stated William Ashton, Chairman of the Board of Spectrum Pharmaceuticals. “As a seasoned executive in M&A and the life sciences sector, Brittany’s experience and leadership will make an immediate impact on our board.”
“I am looking forward to joining Spectrum’s Board at a time when the company has two product candidates that are under FDA review and approaching potential commercialization,” said Ms. Bradrick. “I intend to add value and contribute to the company's mission of developing and delivering innovative medicines for patients with cancer.”
Ms. Bradrick has served as the Chief Financial Officer of Neurelis, Inc. since October 2021. Prior to joining Neurelis, Ms. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as Vice President, Strategy & Corporate Development and at Abbott Diabetes Care as the Head of Global Business Development. Prior to these positions, Ms. Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. Ms. Bradrick began her career as a Federal Reserve Bank Examiner. Ms. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.
AboutSpectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
What does Brittany Bradrick's appointment mean for Spectrum Pharmaceuticals (SPPI)?
Brittany Bradrick's appointment to the Board is expected to enhance strategic initiatives and governance, especially as SPPI navigates FDA reviews for its product candidates.
What is Brittany Bradrick's background before joining Spectrum Pharmaceuticals (SPPI)?
Brittany Bradrick has 25 years of experience in finance and corporate development, previously serving as CFO of Neurelis and COO at ViaCyte.
When was Brittany Bradrick appointed to the Board of Spectrum Pharmaceuticals (SPPI)?
Brittany Bradrick was appointed to the Board of Spectrum Pharmaceuticals on the announcement date of the press release.
How might Brittany Bradrick's experience impact Spectrum Pharmaceuticals (SPPI)?
Her extensive experience in M&A and corporate strategy may provide valuable insights and direction as SPPI seeks to commercialize its product candidates.
